Quotient Clinical is expanding its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis labs.
 
The new labs, based within the company’s Nottingham facility, will provide formulation development services with a footprint of approximately 8,000 sq.-ft. The new GMP manufacturing facility, located in the MediCity innovation hub in Nottingham, has a footprint of 3,000 sq.-ft. and comprises eight multipurpose suites for the manufacture of drug products on a large scale, with the necessary containment controls to handle high potency molecules. The facility is scheduled to become operational later in 2015 following an MHRA inspection.
 
Mark Egerton, chief executive officer Quotient Clinical said, “This expansion is in direct response to the increasing demand for our Translational Pharmaceutics services. Our approach of integrating formulation development, real-time GMP manufacturing and clinical testing is proving an attractive option to reduce development timelines and associated costs.”